Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000813961 | SCV000954348 | pathogenic | Li-Fraumeni syndrome | 2018-12-21 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Glu285 amino acid residue in TP53. Other variant(s) that disrupt this residue have been observed in individuals with TP53-related conditions (PMID: 11051239, 22507745, 23894400), suggesting that it is a clinically significant residue. As a result, variants that disrupt this residue are likely to be causative of disease. This variant has been reported to affect TP53 protein function (PMID: 12826609, 18762572, 25584008). This variant has been observed to be de novo in an individual affected with pediatric adrenocortical carcinoma and choroid plexus carcinoma (PMID: 18762572, 25584008). ClinVar contains an entry for this variant (Variation ID: 12384). This variant is present in population databases (rs121912667, ExAC 0.002%). This sequence change replaces glutamic acid with valine at codon 285 of the TP53 protein (p.Glu285Val). The glutamic acid residue is highly conserved and there is a moderate physicochemical difference between glutamic acid and valine. |
OMIM | RCV000013184 | SCV000033431 | pathogenic | Adrenocortical carcinoma, pediatric | 2008-09-01 | no assertion criteria provided | literature only | |
OMIM | RCV000013185 | SCV000033432 | pathogenic | Choroid plexus carcinoma | 2008-09-01 | no assertion criteria provided | literature only |